KAM
CCCC icon

Kazazian Asset Management’s C4 Therapeutics CCCC Stock Holding History

Kazazian Asset Management’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-14,250
Closed -$51.3K – 66
2024
Q4 		$51.3K Buy
+14,250
New +$70.9K 0.04% 60

Other funds holding CCCC

LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Kazazian Asset Management's CCCC Position: Q1 2025 in Review

Kazazian Asset Management sold out of C4 Therapeutics (CCCC) in Q1 2025, closing a stake of 14,250 shares — an estimated $51.3K sold.

Kazazian Asset Management first reported a position in CCCC in Q4 2024 and held it in 1 quarter. The position peaked at $51.3K in Q4 2024. 114 funds tracked by Wall St. Rank hold CCCC as of Q1 2025.

  • Kazazian Asset Management reported no remaining C4 Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Kazazian Asset Management sold 14,250 C4 Therapeutics shares in Q1 2025, an estimated $51.3K.
  • Kazazian Asset Management first reported a position in C4 Therapeutics in Q4 2024 and held it in 1 quarter.
  • Kazazian Asset Management's C4 Therapeutics position peaked at $51.3K in Q4 2024.
  • 114 funds tracked by Wall St. Rank held C4 Therapeutics as of Q1 2025.

Based on Kazazian Asset Management's 13F filing for Q1 2025, filed 9 May 2025.